Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

HIV protease inhibitors decrease VEGF/HIF-1alpha expression and angiogenesis in glioblastoma cells.

Nabendu Pore1, Anjali K Gupta, George J Cerniglia

  • 1Department of Radiation Oncology, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA.

Neoplasia (New York, N.Y.)
|November 30, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

FOLR1-targeted actinium-225-based alpha-particle therapy eliminates ovarian cancer.

Science advances·2026
Same author

Topical resiquimod elicits systemic protection and improves anti-PD1 therapy in melanoma via priming of CD8+ T cells.

Cancer immunology research·2026
Same author

Estrogen receptor β target gene expression reveals novel repressive functions in aggressive breast cancer.

NPJ breast cancer·2026
Same author

FOLR1-targeted Actinium-225-based Alpha-particle Therapy Eliminates Ovarian Cancer.

bioRxiv : the preprint server for biology·2025
Same author

Preliminary evaluation of the safety and feasibility of toll-like receptor ligand CB101 combined with hypofractionated radiation therapy in canine head and neck cancer: a pilot study.

Veterinary oncology (London, England)·2025
Same author

Enhancing outcomes in medically inoperable early-stage NSCLC with gut-targeted antibiotics and stereotactic body radiotherapy: results from a randomized pilot study.

Journal for immunotherapy of cancer·2025
Same journal

The importance of HPV testing in oropharyngeal cancer in two US populations.

Neoplasia (New York, N.Y.)·2026
Same journal

Multi-omics characterization of radiation-induced cerebellar remodeling and tumorigenic transcriptional programs.

Neoplasia (New York, N.Y.)·2026
Same journal

Deep learning of pretreatment ascites cytopathology for platinum-resistance risk stratification in advanced epithelial ovarian cancer.

Neoplasia (New York, N.Y.)·2026
Same journal

The benefit of deep genomic testing for asymptomatic high-risk individuals undergoing surveillance for pancreatic adenocarcinoma: European registry for hereditary pancreatic diseases (EUROPAC-PLUS).

Neoplasia (New York, N.Y.)·2026
Same journal

Heterogeneous SPP1-expressing esophageal cancer cells license immunotherapy resistance by organizing an immunosuppressive niche.

Neoplasia (New York, N.Y.)·2026
Same journal

Fusion gene heterogeneity and kinase enrichment in high-grade serous carcinomas.

Neoplasia (New York, N.Y.)·2026
See all related articles

Two HIV protease inhibitors, nelfinavir and amprenavir, reduced vascular endothelial growth factor (VEGF) and hypoxia-inducible factor (HIF)-1alpha expression, inhibiting angiogenesis in glioblastoma models. These findings suggest potential therapeutic applications for these drugs in treating malignant brain tumors.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Glioblastomas are aggressive brain tumors with poor prognoses, often driven by activated signaling pathways like PI3K.
  • Loss of PTEN or EGFR activation in glioblastomas leads to PI3K pathway activation, promoting tumor growth and angiogenesis via VEGF and HIF-1alpha.
  • Current glioblastoma treatments are often insufficient, necessitating novel therapeutic strategies.

Purpose of the Study:

  • To investigate the anti-angiogenic and anti-tumor effects of HIV protease inhibitors nelfinavir and amprenavir in glioblastoma.
  • To determine the impact of these inhibitors on key signaling molecules, including Akt, VEGF, and HIF-1alpha.
  • To evaluate the potential of nelfinavir and amprenavir in preclinical glioblastoma models.

Main Methods:

Related Experiment Videos

  • Assessing the effects of nelfinavir and amprenavir on VEGF and HIF-1alpha expression under normoxic and hypoxic conditions.
  • Investigating the role of the PI3K/Akt pathway in mediating the effects of nelfinavir on VEGF.
  • Evaluating the impact of nelfinavir on angiogenesis using in vivo Matrigel plug assays.

Main Results:

  • Nelfinavir significantly decreased VEGF mRNA and protein secretion, an effect linked to Akt pathway inhibition.
  • Both nelfinavir and amprenavir reduced the hypoxia-induced expression of VEGF and HIF-1alpha.
  • Nelfinavir's inhibition of HIF-1alpha appeared to be mediated by decreased protein translation.
  • In vivo studies demonstrated that nelfinavir effectively reduced angiogenesis.

Conclusions:

  • HIV protease inhibitors nelfinavir and amprenavir exhibit anti-angiogenic properties relevant to glioblastoma treatment.
  • These drugs modulate critical pathways (PI3K/Akt, VEGF, HIF-1alpha) involved in glioblastoma progression.
  • Further clinical investigation of nelfinavir and amprenavir is warranted for glioblastoma therapy.